Renewed Political Pressure on Hydroxychloroquine for COVID Highlights Need For Independent US FDA
Executive Summary
Bowing to President Trump’s latest push to authorize the anti-malarial drug for COVID-19 could damage the reputation of the agency for the duration of the pandemic and beyond, experts say, arguing it may be the best example yet of why the FDA’s decision making needs to be more clearly delineated from the country’s political leadership.
You may also be interested in...
Biden’s Trump Moment? COVID Booster Messaging Complicated After Top FDA Scientists Raise Doubts
As questions of political interference continue to swirl around the issue of whether additional vaccine shots will be needed, the Biden administration is facing communication challenges commonly seen with his predecessor, Donald Trump.
FDA, CDC Leaders Under Trump Urge Fixed Terms For US Health Agency Heads
Former FDA Commissioner Stephen Hahn and former CDC Director Robert Redfield said leaders of their agencies and NIH should be selected outside the election schedule. White House task force reviewing political interference with agency science.
Hahn Urges Fixed Terms For US FDA Leaders
Former commissioner Stephen Hahn and former CDC Director Robert Redfield said leaders of their agencies and NIH should be selected outside the election schedule. White House task force reviewing political interference with agency science.